Literature DB >> 15239632

Is severe intestinal chronic graft-versus-host disease an indication for surgery? A report of two cases.

Andrée-Laure Herr1, Jean-François Latulippe, Stéphane Carignan, Andrew Mitchell, Robert Bélanger, Jean Roy.   

Abstract

Chronic graft-versus-host disease (cGVHD) frequently complicates allogeneic hematopoietic stem cell transplantation (HSCT), but small bowel involvement with obstruction is rarely observed. We report two patients who underwent allogeneic sibling HSCT and developed severe cGVHD involving the small bowel, causing unremitting obstructive symptoms and malnutrition despite maximal immunosuppression. Both patients underwent ileal resection and stricturoplasties. The first patient promptly improved, and remains asymptomatic 32 months after transplant. Three weeks after the resection of 90 cm of small bowel, the second patient developed leaking stricturoplasty and peritonitis, with a relapse of chronic myelogenous leukemia in accelerated phase. Later, an enterocutaneous fistula required additional small bowel resection and ileostomy. The patient subsequently died from pulmonary infection a few weeks after the last surgical procedure. Similar to inflammatory bowel disease, these two cases highlight that surgery may be a valuable option in patients who present with obstructive severe cGVHD refractory to aggressive immunosuppression.

Entities:  

Mesh:

Year:  2004        PMID: 15239632     DOI: 10.1097/01.tp.0000127251.16608.8f

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Chronic graft versus host disease with small bowel obstruction after unrelated hematopoietic stem cell transplantation in a patient with acute myeloid leukemia.

Authors:  Ju Young Yoon; Hyery Kim; Hyoung Jin Kang; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  Korean J Hematol       Date:  2012-06-26

2.  Ileostomy for steroid-resistant acute graft-versus-host disease of the gastrointestinal tract.

Authors:  Amin T Turki; Evren Bayraktar; Oliver Basu; Tamas Benkö; Ji-Hee Yi; Jan Kehrmann; Asterios Tzalavras; Tobias Liebregts; Dietrich W Beelen; Nina K Steckel
Journal:  Ann Hematol       Date:  2019-07-23       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.